"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2006-12

AUTHORS

Amit Agrawal, John F R Robertson, K L Cheung

ABSTRACT

BACKGROUND: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal. METHODS: Data was retrieved from a prospectively updated database of metastatic breast cancer. Relevant data was exported to SPSS software for statistical analysis. RESULTS: In oestrogen receptor (ER) positive MBC patients with assessable disease, CB was achieved in 159 (71.3%) (1st line) patients. When these patients were put on further endocrine therapy, the CB rates were 63.2% (on 2nd line), 46.1% (on 3rd line) and 20% (on 4th line) with a median duration of response (DOR) in those with CB of 22, 12, 11 and 15 months respectively. The remaining 64 (28.7%) patients had de novo resistance on 1st line endocrine therapy. Seventeen of these patients were treated with further endocrine therapy. The CB rates were 29.4% (on 2nd line) and 22.2% (on 3rd line) with a median DOR in those with CB of 22.7 months and 14 months respectively. CONCLUSION: The chance of further endocrine response continues to decrease with each line of therapy, yet CB is still seen with reasonable duration even with a 4th line agent. In addition, further endocrine response, with long duration, can be seen in a significant proportion of patients who have developed de novo resistance to 1st line endocrine therapy. The use of further endocrine therapy should not be excluded under these circumstances. More... »

PAGES

40

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1477-7819-4-40

DOI

http://dx.doi.org/10.1186/1477-7819-4-40

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020103401

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16822312


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agrawal", 
        "givenName": "Amit", 
        "id": "sg:person.01036236301.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036236301.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "John F R", 
        "id": "sg:person.07764637207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheung", 
        "givenName": "K L", 
        "id": "sg:person.016477423232.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016477423232.32"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1023983032625", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001709392", 
          "https://doi.org/10.1023/a:1023983032625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1987.14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004831077", 
          "https://doi.org/10.1038/bjc.1987.14"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1987.14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004831077", 
          "https://doi.org/10.1038/bjc.1987.14"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(74)91364-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006753414"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011360956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.11764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013693142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1005828731462", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018344209", 
          "https://doi.org/10.1023/a:1005828731462"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00689685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019965929", 
          "https://doi.org/10.1007/bf00689685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-04-0110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021321766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1992.153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022813323", 
          "https://doi.org/10.1038/bjc.1992.153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1992.153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022813323", 
          "https://doi.org/10.1038/bjc.1992.153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1677/erc.1.01108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025619483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1677/erc.1.01108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025619483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(97)00178-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030310702"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-004-4776-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031540377", 
          "https://doi.org/10.1007/s10549-004-4776-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0360-3016(83)90286-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031856738"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.05.145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037375825"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjsurg.2004.06.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048578512"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/02841869609083979", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049839415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1160/th03-07-0467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063289951"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.09.099", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203852"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-12", 
    "datePublishedReg": "2006-12-01", 
    "description": "BACKGROUND: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal.\nMETHODS: Data was retrieved from a prospectively updated database of metastatic breast cancer. Relevant data was exported to SPSS software for statistical analysis.\nRESULTS: In oestrogen receptor (ER) positive MBC patients with assessable disease, CB was achieved in 159 (71.3%) (1st line) patients. When these patients were put on further endocrine therapy, the CB rates were 63.2% (on 2nd line), 46.1% (on 3rd line) and 20% (on 4th line) with a median duration of response (DOR) in those with CB of 22, 12, 11 and 15 months respectively. The remaining 64 (28.7%) patients had de novo resistance on 1st line endocrine therapy. Seventeen of these patients were treated with further endocrine therapy. The CB rates were 29.4% (on 2nd line) and 22.2% (on 3rd line) with a median DOR in those with CB of 22.7 months and 14 months respectively.\nCONCLUSION: The chance of further endocrine response continues to decrease with each line of therapy, yet CB is still seen with reasonable duration even with a 4th line agent. In addition, further endocrine response, with long duration, can be seen in a significant proportion of patients who have developed de novo resistance to 1st line endocrine therapy. The use of further endocrine therapy should not be excluded under these circumstances.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1477-7819-4-40", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032056", 
        "issn": [
          "1477-7819"
        ], 
        "name": "World Journal of Surgical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "\"Resurrection of clinical efficacy\" after resistance to endocrine therapy in metastatic breast cancer", 
    "pagination": "40", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5fc9373a75c003d5de9058e776f1bc16a4b38034959edea2ba7ff182331edee4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16822312"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101170544"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1477-7819-4-40"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020103401"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1477-7819-4-40", 
      "https://app.dimensions.ai/details/publication/pub.1020103401"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000512.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1477-7819-4-40"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-40'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-40'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-40'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-40'


 

This table displays all metadata directly associated to this object as RDF triples.

145 TRIPLES      21 PREDICATES      47 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1477-7819-4-40 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N13b1926344d44a4fb9fea99f4d85ff3e
4 schema:citation sg:pub.10.1007/bf00689685
5 sg:pub.10.1007/s10549-004-4776-0
6 sg:pub.10.1023/a:1005828731462
7 sg:pub.10.1023/a:1023983032625
8 sg:pub.10.1038/bjc.1987.14
9 sg:pub.10.1038/bjc.1992.153
10 https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f
11 https://doi.org/10.1002/cncr.11764
12 https://doi.org/10.1016/0360-3016(83)90286-9
13 https://doi.org/10.1016/j.amjsurg.2004.06.017
14 https://doi.org/10.1016/s0140-6736(74)91364-6
15 https://doi.org/10.1016/s0959-8049(97)00178-0
16 https://doi.org/10.1158/1078-0432.ccr-04-0110
17 https://doi.org/10.1160/th03-07-0467
18 https://doi.org/10.1200/jco.2003.09.099
19 https://doi.org/10.1200/jco.2005.05.145
20 https://doi.org/10.1677/erc.1.01108
21 https://doi.org/10.3109/02841869609083979
22 schema:datePublished 2006-12
23 schema:datePublishedReg 2006-12-01
24 schema:description BACKGROUND: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal. METHODS: Data was retrieved from a prospectively updated database of metastatic breast cancer. Relevant data was exported to SPSS software for statistical analysis. RESULTS: In oestrogen receptor (ER) positive MBC patients with assessable disease, CB was achieved in 159 (71.3%) (1st line) patients. When these patients were put on further endocrine therapy, the CB rates were 63.2% (on 2nd line), 46.1% (on 3rd line) and 20% (on 4th line) with a median duration of response (DOR) in those with CB of 22, 12, 11 and 15 months respectively. The remaining 64 (28.7%) patients had de novo resistance on 1st line endocrine therapy. Seventeen of these patients were treated with further endocrine therapy. The CB rates were 29.4% (on 2nd line) and 22.2% (on 3rd line) with a median DOR in those with CB of 22.7 months and 14 months respectively. CONCLUSION: The chance of further endocrine response continues to decrease with each line of therapy, yet CB is still seen with reasonable duration even with a 4th line agent. In addition, further endocrine response, with long duration, can be seen in a significant proportion of patients who have developed de novo resistance to 1st line endocrine therapy. The use of further endocrine therapy should not be excluded under these circumstances.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N5ed2f891c50140c59572970e26191aad
29 Ned5c0b5c7e8e41f1a5d8d7ab7fc0001b
30 sg:journal.1032056
31 schema:name "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer
32 schema:pagination 40
33 schema:productId N09429d41cd2b424eb69c39f420ca9cd2
34 N126167e2d2d9453faae126294c8d12d0
35 N49b0160cd06744cdbebbbfa08632ed53
36 Na73ea247e3dd4896b906752aafddabc4
37 Nc23a23490f1b42c89e34d494445fed70
38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020103401
39 https://doi.org/10.1186/1477-7819-4-40
40 schema:sdDatePublished 2019-04-10T18:20
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N62f0322f957240faa318d349d2fabe5d
43 schema:url http://link.springer.com/10.1186%2F1477-7819-4-40
44 sgo:license sg:explorer/license/
45 sgo:sdDataset articles
46 rdf:type schema:ScholarlyArticle
47 N09429d41cd2b424eb69c39f420ca9cd2 schema:name doi
48 schema:value 10.1186/1477-7819-4-40
49 rdf:type schema:PropertyValue
50 N126167e2d2d9453faae126294c8d12d0 schema:name readcube_id
51 schema:value 5fc9373a75c003d5de9058e776f1bc16a4b38034959edea2ba7ff182331edee4
52 rdf:type schema:PropertyValue
53 N13b1926344d44a4fb9fea99f4d85ff3e rdf:first sg:person.01036236301.85
54 rdf:rest Nabc6b612925948c78d89f2adfb61d457
55 N374c0380cd674a29b857a016f578941f schema:name Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK
56 rdf:type schema:Organization
57 N4202034e2f6a416a833ad02610fc20f9 rdf:first sg:person.016477423232.32
58 rdf:rest rdf:nil
59 N49b0160cd06744cdbebbbfa08632ed53 schema:name dimensions_id
60 schema:value pub.1020103401
61 rdf:type schema:PropertyValue
62 N55434d3ecd4242e7b545c595cdad37e2 schema:name Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK
63 rdf:type schema:Organization
64 N5ed2f891c50140c59572970e26191aad schema:issueNumber 1
65 rdf:type schema:PublicationIssue
66 N62f0322f957240faa318d349d2fabe5d schema:name Springer Nature - SN SciGraph project
67 rdf:type schema:Organization
68 Na73ea247e3dd4896b906752aafddabc4 schema:name nlm_unique_id
69 schema:value 101170544
70 rdf:type schema:PropertyValue
71 Nabc1a91dec4a464b90f4a215a3dafbe8 schema:name Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK
72 rdf:type schema:Organization
73 Nabc6b612925948c78d89f2adfb61d457 rdf:first sg:person.07764637207.20
74 rdf:rest N4202034e2f6a416a833ad02610fc20f9
75 Nc23a23490f1b42c89e34d494445fed70 schema:name pubmed_id
76 schema:value 16822312
77 rdf:type schema:PropertyValue
78 Ned5c0b5c7e8e41f1a5d8d7ab7fc0001b schema:volumeNumber 4
79 rdf:type schema:PublicationVolume
80 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
81 schema:name Medical and Health Sciences
82 rdf:type schema:DefinedTerm
83 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
84 schema:name Oncology and Carcinogenesis
85 rdf:type schema:DefinedTerm
86 sg:journal.1032056 schema:issn 1477-7819
87 schema:name World Journal of Surgical Oncology
88 rdf:type schema:Periodical
89 sg:person.01036236301.85 schema:affiliation Nabc1a91dec4a464b90f4a215a3dafbe8
90 schema:familyName Agrawal
91 schema:givenName Amit
92 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036236301.85
93 rdf:type schema:Person
94 sg:person.016477423232.32 schema:affiliation N55434d3ecd4242e7b545c595cdad37e2
95 schema:familyName Cheung
96 schema:givenName K L
97 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016477423232.32
98 rdf:type schema:Person
99 sg:person.07764637207.20 schema:affiliation N374c0380cd674a29b857a016f578941f
100 schema:familyName Robertson
101 schema:givenName John F R
102 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20
103 rdf:type schema:Person
104 sg:pub.10.1007/bf00689685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019965929
105 https://doi.org/10.1007/bf00689685
106 rdf:type schema:CreativeWork
107 sg:pub.10.1007/s10549-004-4776-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031540377
108 https://doi.org/10.1007/s10549-004-4776-0
109 rdf:type schema:CreativeWork
110 sg:pub.10.1023/a:1005828731462 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018344209
111 https://doi.org/10.1023/a:1005828731462
112 rdf:type schema:CreativeWork
113 sg:pub.10.1023/a:1023983032625 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001709392
114 https://doi.org/10.1023/a:1023983032625
115 rdf:type schema:CreativeWork
116 sg:pub.10.1038/bjc.1987.14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004831077
117 https://doi.org/10.1038/bjc.1987.14
118 rdf:type schema:CreativeWork
119 sg:pub.10.1038/bjc.1992.153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022813323
120 https://doi.org/10.1038/bjc.1992.153
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f schema:sameAs https://app.dimensions.ai/details/publication/pub.1011360956
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1002/cncr.11764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013693142
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1016/0360-3016(83)90286-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031856738
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1016/j.amjsurg.2004.06.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048578512
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1016/s0140-6736(74)91364-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006753414
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1016/s0959-8049(97)00178-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030310702
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1158/1078-0432.ccr-04-0110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021321766
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1160/th03-07-0467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063289951
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1200/jco.2003.09.099 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203852
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1200/jco.2005.05.145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037375825
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1677/erc.1.01108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025619483
143 rdf:type schema:CreativeWork
144 https://doi.org/10.3109/02841869609083979 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049839415
145 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...